Vera Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Vera Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Brisbane
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- VERA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001831828
- EIN
- 81-2744449
Board of directors
-
Andrew Cheng · DirectorSince 2023
- Since 2023
-
Christopher Hite · DirectorSince 2026
- Since 2024
-
James R. Meyers · DirectorSince 2025
-
Kimball Hall · DirectorSince 2023
-
Maha Katabi · DirectorSince 2023
-
Marshall Fordyce · Director · PRESIDENT AND CEOSince 2023
-
Michael Morrissey · DirectorSince 2023
- Since 2023
- Since 2023
Chief executives
Marshall Fordyce
· PRESIDENT AND CEO
Dates unknown
Director election results
Annual meeting of May 21, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
92.6%
-
99.7%
Board connections
9 of this board's directors also sit on 23 other boards.
- via Christy J. Oliger and Patrick G. Enright
- via James R. Meyers
- via Beth C. Seidenberg
- via Christy J. Oliger
- via Patrick G. Enright
- via Scott W. Morrison
- via James R. Meyers
- via Andrew Cheng
- via Michael Morrissey
- via Scott W. Morrison
- via Maha Katabi
- via Patrick G. Enright
- via Christopher Hite
- via Christy J. Oliger
- via Beth C. Seidenberg
- via Beth C. Seidenberg
- via Beth C. Seidenberg
- via Christy J. Oliger
- via Beth C. Seidenberg
- via Andrew Cheng
- via Scott W. Morrison
- via Patrick G. Enright
- via Scott W. Morrison
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $249,985
- 1 purchase by 1 insider
- Sold, last 12 months
- $8,986,045
- 25 sales by 8 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 15, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Option exercise | +18,500 | $2.90 | $53,591 |
| Sep 15, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −18,500 | $37.00 | $684,500 |
| Sep 11, 2026 | Young Joseph R Officer (SVP, FINANCE, CHIEF ACCT OFFCR) | Option exercise | +5,000 | $3.94 | $19,698 |
| Sep 2, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Option exercise | +18,500 | $2.90 | $53,591 |
| Sep 2, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −18,500 | $35.12 | $649,642 |
| Aug 3, 2026 | Boman Nancy Lee Officer (Chief Regulatory Officer) | Grant or award | +44,987 | — | — |
| Jul 7, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −1,000 | $40.78 | $40,776 |
| Jul 7, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −32,550 | $42.07 | $1,369,496 |
| Jul 7, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −10,500 | $42.86 | $450,007 |
| Jul 7, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −2,200 | $43.59 | $95,908 |
| Jun 23, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −18,412 | $37.93 | $698,367 |
| Jun 23, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −88 | $38.43 | $3,382 |
| May 12, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −14,219 | $36.64 | $520,984 |
| May 12, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −4,281 | $37.09 | $158,782 |
| Apr 14, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −14,130 | $43.66 | $616,916 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.